NCT02734004 2026-04-20
MEDIOLA
AstraZeneca
Phase 1/2 Active not recruiting
Clinical Trials
13 trialsNCT06131840 2026-04-20
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Seagen Inc.
Phase 1 Recruiting
NCT07472647 2026-03-16
SYS6090 Combination Therapy in Advanced Lung Cancer
Shanghai JMT-Bio Inc.
Phase 1/2 Not yet recruiting
NCT06047379 2026-03-02
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
Phase 1/2 Recruiting
NCT05588388 2025-11-17
BELIEVE
Cedars-Sinai Medical Center
Phase 2 Recruiting
NCT04730999 2024-07-05
CeLEBrATE
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 2 Completed
NCT00930891 2016-03-10
CPC
Intergroupe Francophone de Cancerologie Thoracique
Phase 2/3 Completed
NCT00755157 2015-10-07
Metronomic Docetaxel and Bevacizumab in Patients With Small Cell Lung Cancer
University Hospital of Crete
Phase 2 Withdrawn
NCT00698516 2012-03-27
Study of Oral Topotecan With Bevacizumab for Recurrent Small Cell Lung Cancer
GlaxoSmithKline
Phase 2 Completed
NCT00317200 2011-05-02
A Study of Paclitaxel Plus Bevacizumab in Patients With Chemosensitive Relapsed Small Cell Lung Cancer
Hoosier Cancer Research Network
Phase 2 Completed
NCT00403403 2011-04-29
A Study of Bevacizumab in Previously Untreated Extensive-Stage Small Cell Lung Cancer (SALUTE)
Genentech, Inc.
Phase 2 Completed
NCT00294931 2010-06-28
Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00308529 2010-06-22
Irinotecan, Carboplatin, Bevacizumab, and Radiation Therapy in the Treatment of Limited Stage Small Cell Lung Cancer
SCRI Development Innovations, LLC
Phase 2 Completed